Bezuclastinib combined with sunitinib for advanced GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial gives patients with advanced GIST access to the investigational drug bezuclastinib combined with sunitinib. It is for people who have already tried imatinib and need another option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You have an advanced GIST tumor that cannot be removed with surgery or has spread.
- You have tried imatinib (Gleevec) and either it stopped working or you couldn't handle it.
- You can't be in another bezuclastinib study or have been in one before.
- You must not be allergic or sensitive to sunitinib (Sutent).
- Your tumor must not have a PDGFRA mutation or be SDH-deficient.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
Hear when a new Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.